Last reviewed · How we verify
recombinant hemagglutinin influenza vaccine
recombinant hemagglutinin influenza vaccine is a Biologic drug developed by The University of Hong Kong. It is currently FDA-approved.
The recombinant hemagglutinin influenza vaccine, developed by The University of Hong Kong, is currently marketed and holds a position in the influenza vaccine market. A key strength is the protection of its core composition through a patent expiring in 2028, providing a period of exclusivity. The primary risk is the intense competition in the influenza vaccine market, where multiple established players operate.
At a glance
| Generic name | recombinant hemagglutinin influenza vaccine |
|---|---|
| Sponsor | The University of Hong Kong |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
- The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study (PHASE4)
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects (PHASE1)
- Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above (PHASE1)
- Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age (PHASE1)
- Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- recombinant hemagglutinin influenza vaccine CI brief — competitive landscape report
- recombinant hemagglutinin influenza vaccine updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI